Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult‐to‐Treat HCV Patients

Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis

“…In the era of DAAs, the treatment of patients with GT3 infection remains a clinical challenge [39]. In some studies, GT3-infected patients and patients with cirrhosis remain difficult to treat [40,41]. Due to the small sample size of GT3 and cirrhotic patients in the PP population, we only conducted subgroup analysis of GT3 and cirrhosis in the ITT population; however, the SVR12 rate may be higher when the PP population is added.…”

Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C

“…Se realizó una búsqueda bibliográfica donde se encontraron series de casos pacientes con fallo a SOF/VEL/VOX que precisaron tratamiento de rescate ( Tabla 1 ). Los antivirales empleados fueron glecaprevir/pibrentasvir (GLE/PIB) junto con RBV, GLE/PIB + SOF + RBV, SOF/VEL/VOX + RBV y SOF/ VEL + RBV [ 2 - 6 ]. Tras comprobar que no había interacciones significativas entre el tratamiento antiviral y su medicación habitual (omeprazol, risperidona, diazepam y desvenlafaxina), finalmente se prescribió GLE/PIB y RBV 600 mg cada 12 horas durante 16 semanas, duración recomendada en pacientes con genotipo 3 pretratados.…”

Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection

“…There are no randomized controlled trials and few published reports (6 studies with 38 patients) addressing rescue treatment after SOF/VEL/VOX failure (Table 1). Of 32 SOF/VEL/VOX nonresponders treated in 6 studies 1,3,[6][7][8][9] with glecaprevir/pibrentasvir (GLE/PIB) (±sofosbuvir (SOF) and/or ±ribavirin for 12, 16, or 24 weeks), 28 (87.5%) achieved SVR12 (1 patient achieved SVR4 and died prior to SVR 12, 2 patients relapsed, and 1 other patient died). One patient had RAS testing after unsuccessful rescue treatment with GLE/PIB +SOF +ribavirin for 16 weeks; NS5A RASs (A30K, L31F, Y93H) were detected, no NS3 or NS5B RASs were detected.…”